[Abstract Only] Randomized Trial: SGLT2 Inhibitor Reduces Adverse Renal Events in Patients with Type 2 Diabetes and Nephropathy
14 Jun, 2019 | 06:49h | UTCCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation – CREDENCE – American College of Cardiology (free)